New Two-Drug attack aims to shrink tumors before surgeons operate
NCT ID NCT07256509
Summary
This study is for people with a specific type of lung cancer (EGFR-positive, non-squamous, stage II-IIIB) that can be removed with surgery. It will test if adding a new drug called SYS6010 to a standard drug (osimertinib) before surgery is more effective and safe than using the standard drug alone. The goal is to shrink the tumor as much as possible before the operation to improve long-term results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.